Helen Walker1, Mervi Pitkanen2, Yusof Rahman3, Sally F Barrington4. 1. West London Mental Health Trust, London, UK. 2. Department of Neuropsychiatry and Memory Disorders, King's College London, London, UK. mervi.pitkanen@kcl.ac.uk. 3. Centre for Inherited Metabolic Disorders, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK. 4. KCL and Guy's and St Thomas' PET Centre, King's College London, King's Health Partners, St. Thomas' Hospital, London, UK.
Abstract
AIM: To examine neuropsychiatric outcomes in adults with hereditary tyrosinaemia type I (HT-1), treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) and correlate these with functional imaging as well as with tyrosine and phenylalanine-tyrosine (Phe:Tyr) ratios. DESIGN: We retrospectively reviewed the medical records of three adult HT-1 patients with a particular focus on their FDG PET/CT brain scans, neuropsychiatric assessment (including neurocognitive assessment and mood and anxiety ratings) as well as mean tyrosine and phenylalanine levels and Phe:Tyr ratios for 3-month period. The patients had been referred to a specialist joint inherited metabolic disorder and neuropsychiatry clinic. They were all on NTBC; two since 6 weeks of age, and one since 9 years of age. RESULTS: All patients performed below the expectation on the formal neurocognitive testing and had raised plasma tyrosine levels and reduced plasma Phe:Tyr ratios. FDG PET/CT-brain scans were normal in two patients and the third patient (treated with NTBC from 6 weeks) had reduced metabolism in temporal and medial frontal areas bilaterally which correlated with the neurocognitive performance. CONCLUSIONS: All three HT-1 patients treated with NTBC had high tyrosine levels, reduced Phe:Tyr ratios and underperformed in neurocognitive testing regardless of the point when the NTBC was first started. One had imaging abnormalities which also correlated with neurocognitive performance. The patient who struggled the most in neurocognitive testing had the highest average plasma tyrosine levels and the lowest Phe:Tyr ratio. Overall, these cases appear to support the previous hypothesis that either the high tyrosine levels or abnormal phenylalanine hydroxylase (PAH) function may well be the causative factor for poor neurocognitive performance. Further systematic, multi-centre studies with a longer follow-up are required to further clarify the relationship between HT-1, NTBC treatment, tyrosine and phenylalanine levels and neurocognitive outcomes.
AIM: To examine neuropsychiatric outcomes in adults with hereditary tyrosinaemia type I (HT-1), treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) and correlate these with functional imaging as well as with tyrosine and phenylalanine-tyrosine (Phe:Tyr) ratios. DESIGN: We retrospectively reviewed the medical records of three adult HT-1 patients with a particular focus on their FDG PET/CT brain scans, neuropsychiatric assessment (including neurocognitive assessment and mood and anxiety ratings) as well as mean tyrosine and phenylalanine levels and Phe:Tyr ratios for 3-month period. The patients had been referred to a specialist joint inherited metabolic disorder and neuropsychiatry clinic. They were all on NTBC; two since 6 weeks of age, and one since 9 years of age. RESULTS: All patients performed below the expectation on the formal neurocognitive testing and had raised plasma tyrosine levels and reduced plasma Phe:Tyr ratios. FDG PET/CT-brain scans were normal in two patients and the third patient (treated with NTBC from 6 weeks) had reduced metabolism in temporal and medial frontal areas bilaterally which correlated with the neurocognitive performance. CONCLUSIONS: All three HT-1 patients treated with NTBC had high tyrosine levels, reduced Phe:Tyr ratios and underperformed in neurocognitive testing regardless of the point when the NTBC was first started. One had imaging abnormalities which also correlated with neurocognitive performance. The patient who struggled the most in neurocognitive testing had the highest average plasma tyrosine levels and the lowest Phe:Tyr ratio. Overall, these cases appear to support the previous hypothesis that either the high tyrosine levels or abnormal phenylalanine hydroxylase (PAH) function may well be the causative factor for poor neurocognitive performance. Further systematic, multi-centre studies with a longer follow-up are required to further clarify the relationship between HT-1, NTBC treatment, tyrosine and phenylalanine levels and neurocognitive outcomes.
Authors: Corinne De Laet; Vanessa Terrones Munoz; Jaak Jaeken; Baudouin François; Dietbrandt Carton; Etienne M Sokal; Bernard Dan; Philippe J Goyens Journal: Dev Med Child Neurol Date: 2011-07-11 Impact factor: 5.449
Authors: Fatiha Bendadi; Tom J de Koning; Gepke Visser; Hubertus C M T Prinsen; Monique G M de Sain; Nanda Verhoeven-Duif; Gerben Sinnema; Francjan J van Spronsen; Peter M van Hasselt Journal: J Pediatr Date: 2013-11-14 Impact factor: 4.406
Authors: A Masurel-Paulet; J Poggi-Bach; M-O Rolland; O Bernard; N Guffon; D Dobbelaere; J Sarles; H Ogier de Baulny; G Touati Journal: J Inherit Metab Dis Date: 2008-01-25 Impact factor: 4.982
Authors: Angela M Sgaravatti; Bethânia A Vargas; Bernardo R Zandoná; Kátia B Deckmann; Francieli J Rockenbach; Tarsila B Moraes; José M Monserrat; Mirian B Sgarbi; Carolina D Pederzolli; Angela T S Wyse; Clóvis M D Wannmacher; Moacir Wajner; Carlos Severo Dutra-Filho Journal: Int J Dev Neurosci Date: 2008-05-28 Impact factor: 2.457
Authors: Willem G van Ginkel; Rianne Jahja; Stephan C J Huijbregts; Anne Daly; Anita MacDonald; Corinne De Laet; David Cassiman; François Eyskens; Irene M L W Körver-Keularts; Philippe J Goyens; Patrick J McKiernan; Francjan J van Spronsen Journal: Orphanet J Rare Dis Date: 2016-06-29 Impact factor: 4.123
Authors: María Luz Couce; Paula Sánchez-Pintos; Luís Aldámiz-Echevarría; Isidro Vitoria; Victor Navas; Elena Martín-Hernández; Camila García-Volpe; Guillem Pintos; Luis Peña-Quintana; Tomás Hernández; David Gil; Félix Sánchez-Valverde; María Bueno; Iria Roca; Encarna López-Ruzafa; Carmen Díaz-Fernández Journal: Medicine (Baltimore) Date: 2019-09 Impact factor: 1.817
Authors: Clara T Nicolas; Caitlin J VanLith; Raymond D Hickey; Zeji Du; Lori G Hillin; Rebekah M Guthman; William J Cao; Benjamin Haugo; Annika Lillegard; Diya Roy; Aditya Bhagwate; Daniel O'Brien; Jean-Pierre Kocher; Robert A Kaiser; Stephen J Russell; Joseph B Lillegard Journal: Nat Commun Date: 2022-08-25 Impact factor: 17.694
Authors: Kimber van Vliet; Willem G van Ginkel; Rianne Jahja; Anne Daly; Anita MacDonald; Saikat Santra; Corinne De Laet; Philippe J Goyens; Roshni Vara; Yusof Rahman; David Cassiman; Francois Eyskens; Corrie Timmer; Nicky Mumford; Paul Gissen; Jörgen Bierau; Peter M van Hasselt; Gisela Wilcox; Andrew A M Morris; Elisabeth A Jameson; Alicia de la Parra; Carolina Arias; Maria I Garcia; Veronica Cornejo; Annet M Bosch; Carla E M Hollak; M Estela Rubio-Gozalbo; Martijn C G J Brouwers; Floris C Hofstede; Maaike C de Vries; Mirian C H Janssen; Ans T van der Ploeg; Janneke G Langendonk; Stephan C J Huijbregts; Francjan J van Spronsen Journal: J Inherit Metab Dis Date: 2022-06-30 Impact factor: 4.750
Authors: Kimber van Vliet; Wiggert G van Ginkel; Esther van Dam; Pim de Blaauw; Martijn Koehorst; Hermi A Kingma; Francjan J van Spronsen; M Rebecca Heiner-Fokkema Journal: Orphanet J Rare Dis Date: 2020-04-03 Impact factor: 4.123